Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TherVacB_Phase1a
NCT05727267Phase 1Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Jan 2024
- Primary completion
- May 2026
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of TherVacB in Chronic Hepatitis B (CHB) (6 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoints: Occurrence of solicited local reactogenicity signs and symptoms (AEs) at Day 63, Occurrence of unsolicited local reactogenicity signs and symptoms at Day 84 and 2 more. Started Jan 2024; status: completed.
02
Drugs
TherVacB
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05727267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727267.